Ruben Mesa, MD, director, UT Health San Antonio Cancer Center, discusses NCCN guideline updates in polycythemia vera and essential thrombocythemia.
Evolving Roles of JAK Inhibitors in Cytopenic Myelofibrosis
September 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, discussed the development of Janus kinase inhibitors and how newer therapies meet needs of patients with cytopenic myelofibrosis.
Read More
Behind the FDA Approval: Momelotinib for Myelofibrosis and Anemia
September 20th 2023In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, delves further into the background of momelotinib, how to manage toxicities with the agent, and its role in clinical practice moving forward.
Read More
2 Clarke Drive
Cranbury, NJ 08512